Tag: Canadian Biotech
-
![Medexus Pharmaceuticals (MDP.TO): A growing core business breaking company records]()
Medexus Pharmaceuticals (MDP.TO): A growing core business breaking company records
*originally published 01-16-23 Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing over drugs that are already licensed in Western Europe and then bringing them to North America. A very smart business model which has seen Medexus carve…
-
Revive Therapeutics (RVV.C) files for FDA Orphan Drug Designation for psilocybin in traumatic brain injury
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function after TBI lessening disability”.
-
![PredictMedix (PMED.C), CFO SECRETLY SOLD SHARES??? (*CLICKBAIT*)]()
PredictMedix (PMED.C), CFO SECRETLY SOLD SHARES??? (*CLICKBAIT*)
Ok weekenders, let’s talk PMED. For the newbies in the room, PMED is PredictMedix Inc, a biotech company Equity Guru’s been working with for the past little bit. (Of course, this doesn’t change the fact that we’re still big on holding people accountable – client or not. See recent example here.) PMED as a business…
-
Revive Therapeutics (RVV.C) shareholders experience intense vertigo
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space.
-
![Revive (RVV.C) stock ramps hard on news from a collaborator]()
Revive (RVV.C) stock ramps hard on news from a collaborator
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”.
-
![Revive (RVV.C) advances mushroom bio-tech as new regs change the game]()
Revive (RVV.C) advances mushroom bio-tech as new regs change the game
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison”. RVV is a specialty life sciences company focused on the R&D of therapeutics for medical needs and rare disorders.…
-
NeuPath Health Inc (NPTH.V): Where a little attention could go a long way
“In Canada, it’s not fundamentals, but sentiment that moves markets”…boy, if I had a nickel for everytime I heard that, I would have invested in Well Health Technologies (WELL.T) (nothing against $WELL!), and I would have been a couple of thousand dollars richer. If only there was a way to prove that. Allow me: It…
-
Revive (RVV.C) gives update on FDA Phase 3 clinical trial
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focused on developing coronavirus solutions.
-
Revive’s (RVV.C) Bucillamine Covid-19 treatment advances through development pipeline
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focussed on developing coronavirus solutions.
-
Revive (RVV.C) advances drug delivery tech for psychedelics
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
